| Literature DB >> 25738397 |
Citlalli Osorio-Yáñez1, Julio C Ayllon-Vergara, Laura Arreola-Mendoza, Guadalupe Aguilar-Madrid, Erika Hernández-Castellanos, Luz C Sánchez-Peña, Luz M Del Razo.
Abstract
BACKGROUND: Inorganic arsenic (iAs) is a ubiquitous element present in the groundwater worldwide. Cardiovascular effects related to iAs exposure have been studied extensively in adult populations. Few epidemiological studies have been focused on iAs exposure-related cardiovascular disease in children.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25738397 PMCID: PMC4455579 DOI: 10.1289/ehp.1307327
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Characteristics, blood pressure, nitric oxide metabolites, total concentration of arsenic species in urine, and lifetime arsenic exposure of children in Zimapan, Mexico.
| Variable | Percent or GM (range) | |
|---|---|---|
| Sex | ||
| Male | 85 | 53 |
| Female | 76 | 47 |
| Yes | 132 | 82 |
| No | 29 | 18 |
| Age (years) | 161 | 5 (3–8) |
| ≤ 5 | 115 | 71 |
| > 5 | 46 | 29 |
| BMI (kg/m2) | 158 | 16 (12–26) |
| 158 | 37 (1–99) | |
| Blood pressure (mmHg) | ||
| Systolic BP | 159 | 87 (70–108) |
| Diastolic BP | 159 | 61 (45–80) |
| Hypertension classification | ||
| Normotensive | 76 | 48 |
| Diastolic prehypertension | 78 | 49 |
| Diastolic hypertension | 4 | 2.5 |
| Mixed hypertension | 1 | 0.6 |
| Plasma glucose (mg/dL) | 156 | 83 (64–130) |
| Nitric oxide metabolites | ||
| Urine NOx (μM) | 158 | 1,140 (249–4,743) |
| Plasma NOx (μM) | 156 | 52.0 (16.7–164) |
| Hemoglobin (g/dL) | 157 | 13.8 (11.7–16.6) |
| Hematocrit (%) | 158 | 39.7 (33.5–46.1) |
| iAs concentration in water (μg/L) (year) | ||
| 2009 | 6 (53) | 25.9 (3–135) |
| 1993–2009 | 6 (237) | 68.1 (3–313) |
| Urinary As ( ng/mL) | ||
| U-iAs | 158 | 5.44 (0.57–101) |
| U-MAs | 158 | 5.40 (0.21–55.7) |
| U-DMAs | 158 | 46.9 (4.93–237) |
| U-tAs | 158 | 59.0 (5.71–370) |
| U-tAs categories (ng/mL) | ||
| < 35 | 34 | 23.4 (5.71–32.8) |
| 35–70 | 68 | 52.7 (35.3–70.0) |
| > 70 | 56 | 119 (70.4–370) |
| U-tAs categories (ng/mL) | ||
| < 46 | 54 | 28.6 (5.71–45.6) |
| 46–72 | 52 | 59.8 (46.8–71.9) |
| > 72 | 52 | 123 (72.5–370) |
| Urinary As (%) | ||
| U-iAs | 158 | 9.22 (2.33–27.2) |
| U-MAs | 158 | 9.16 (1.50–18.0) |
| U-DMAs | 158 | 79.5 (29.2–91.5) |
| LAsE (μg/L-year) | 159 | 432 (14.0–1,255) |
| LAsE categories (μg/L-year) | ||
| < 382 | 52 | 214 (14.0–382) |
| 382–620 | 57 | 523 (391–609) |
| > 620 | 50 | 725 (622–1,255) |
| GM, geometric mean. | ||
Structural and functional echocardiographic parameters in children exposed to inorganic arsenic.
| Variable | GM (95% CI) | Mean ± SD | |
|---|---|---|---|
| Structural echocardiographic parameters | |||
| ARD (mm) | 145 | 14.0 (13.7, 14.3) | 14.1 ± 1.93 |
| LAD (mm) | 158 | 20.8 (20.3, 21.3) | 21.0 ± 2.88 |
| LVEDV (mL) | 161 | 37.5 (36.0, 39.2) | 38.9 ± 10.0 |
| LVESV (mL) | 161 | 10.5 (9.91, 11.1) | 11.2 ± 3.74 |
| LVIDD (cm) | 161 | 3.08 (3.03, 3.14) | 3.10 ± 0.34 |
| LVISD (cm) | 161 | 1.86 (1.82, 1.90) | 1.88 ± 0.25 |
| PWTD (cm) | 161 | 0.74 (0.72, 0.77) | 0.76 ± 0.16 |
| IVSTD (cm) | 161 | 0.71 (0.69, 0.72) | 0.72 ± 0.11 |
| LVM (g) | 161 | 54.6 (52.8, 56.5) | 56.0 ± 13.0 |
| LVMI (g/m2) | 160 | 67.9 (66.0, 69.8) | 69.0 ± 12.3 |
| RWT | 161 | 0.48 (0.46, 0.50) | 0.50 ± 0.15 |
| Functional echocardiographic parameters | |||
| Systolic function | |||
| LV EF (%) | 161 | 70.2 (68.9, 71.6) | 70.7 ± 8.31 |
| LV SF (%) | 161 | 38.5 (37.3, 39.7) | 39.3 ± 7.30 |
| Diastolic function | |||
| Mitral E/A ratio | 157 | 1.68 (1.62, 1.74) | 1.73 ± 0.40 |
| Mitral E DT (msec) | 156 | 126 (122, 131) | 129 ± 28.1 |
| LV geometry pattern | |||
| Group of children [ | |||
| Normal | 50 (31.2) | ||
| Concentric hypertrophy | 11 (6.9) | ||
| Concentric remodeling | 99 (61.9) | ||
| Abbreviations: ARD, aortic root diameter; GM, geometric mean; IVSTD, interventricular septum thickness in diastole; LAD, left atrium diameter; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; LVIDD, left ventricular internal diastolic diameter; LVISD, left ventricular internal systolic diameter; LVM, left ventricular mass; LVSF, left ventricular shortening fraction; mitral E DT, mitral E deceleration time; PWTD, posterior wall thickness in diastole; RWT, relative wall thickness. | |||
Multivariate regression analyses of systolic and diastolic blood pressure in association with chronic exposure (LAsE) and current exposure (U-tAs) to inorganic arsenic in children.
| Explanatory variable | β (95% CI) | |
|---|---|---|
| Systolic blood pressure | ||
| LAsE (μg/L-year) | –0.001 (–0.005, 0.003) | 0.700 |
| U-tAs (ng/mL) | 0.021 (0.004, 0.037) | 0.015 |
| Diastolic blood pressure | ||
| LAsE (μg/L-year) | 0.0006 (–0.003, 0.004) | 0.741 |
| U-tAs (ng/mL) | 0.013 (0.002, 0.024) | 0.023 |
| Abbreviations: LAsE, estimate lifetime arsenic exposure at the individual level; U-tAs, urine arsenic concentration measured concurrently with the outcomes. | ||
Figure 1Simple linear regression analyses of left ventricular mass (A) and aortic root diameter (B) in association with lifetime arsenic exposure (LAsE) > 620 μg/L-year compared with LAsE < 382 μg/L-year (*p < 0.05, **p < 0.01). Simple linear regression analyses of ejection fraction (C) and shortening fraction (D) in association with U-tAs > 70 ng/mL compared with U-tAs < 35 ng/mL (p ≤ 0.1).
Robust multivariable regression analyses of cardiac morphological variables or left ventricular systolic function in association with chronic exposure (LAsE) and current exposure (U-tAs) to inorganic arsenic in children.
| Explanatory variable | β (95% CI) | |
|---|---|---|
| Left ventricular mass | ||
| LAsE (382–620 μg/L-year) | 0.71 (–3.44, 4.86) | 0.736 |
| LAsE (> 620 μg/L-year) | 5.5 (0.65, 10.3) | 0.026 |
| U-tAs (ng/mL) | 0.004 (–0.022, 0.03) | 0.752 |
| Ejection fraction | ||
| LAsE (μg/L-year) | 0.002 (–0.005, 0.008) | 0.572 |
| U-tAs (35–70 ng/mL) | –2.37 (–5.90, 1.16) | 0.186 |
| U-tAs (> 70 ng/mL) | –3.67 (–7.14, –0.20) | 0.038 |
| Shortening fraction | ||
| LAsE (μg/L-year) | 0.002 (–0.003, 0.008) | 0.446 |
| U-tAs (35–70 ng/mL) | –2.55 (–5.76, 0.65) | 0.118 |
| U-tAs (> 70 ng/mL) | –3.41 (–6.44, –0.37) | 0.028 |
| Left atrium diameter | ||
| LAsE (μg/L-year) | 0.0013 (–0.0007, 0.0032) | 0.202 |
| U-tAs (35–70 ng/mL) | 1.13 (–0.11, 2.40) | 0.074 |
| U-tAs (> 70 ng/mL) | 0.46 (–0.88, 1.80) | 0.499 |
| Aortic root diameter | ||
| LAsE (382–620 μg/L-year) | –0.021 (–0.64, 0.60) | 0.947 |
| LAsE (> 620 μg/L-year) | 1.05 (0.31, 1.80) | 0.006 |
| U-MAs (ng/mL) | 0.04 (0.005, 0.070) | 0.023 |
| Abbreviations: LAsE, estimated lifetime arsenic exposure at the individual level; U-tAs, urine arsenic concentration measured concurrently with the outcomes. | ||